SG10202012179RA - Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same - Google Patents
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the sameInfo
- Publication number
- SG10202012179RA SG10202012179RA SG10202012179RA SG10202012179RA SG10202012179RA SG 10202012179R A SG10202012179R A SG 10202012179RA SG 10202012179R A SG10202012179R A SG 10202012179RA SG 10202012179R A SG10202012179R A SG 10202012179RA SG 10202012179R A SG10202012179R A SG 10202012179RA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- same
- isoindoline derivatives
- arylmethoxy isoindoline
- Prior art date
Links
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30361810P | 2010-02-11 | 2010-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202012179RA true SG10202012179RA (en) | 2021-01-28 |
Family
ID=43708752
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012059259A SG183257A1 (en) | 2010-02-11 | 2011-02-10 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
SG10202012179RA SG10202012179RA (en) | 2010-02-11 | 2011-02-10 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
SG10201501062SA SG10201501062SA (en) | 2010-02-11 | 2011-02-10 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012059259A SG183257A1 (en) | 2010-02-11 | 2011-02-10 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201501062SA SG10201501062SA (en) | 2010-02-11 | 2011-02-10 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
Country Status (32)
Country | Link |
---|---|
US (8) | US8518972B2 (es) |
EP (6) | EP4289838A3 (es) |
JP (5) | JP2013519675A (es) |
KR (2) | KR101931468B1 (es) |
CN (2) | CN102822165B (es) |
AR (1) | AR081058A1 (es) |
AU (1) | AU2011215877C1 (es) |
CA (1) | CA2787823C (es) |
CO (1) | CO6571916A2 (es) |
CR (1) | CR20120414A (es) |
CY (3) | CY1119177T1 (es) |
DK (3) | DK2536706T3 (es) |
EC (1) | ECSP12012098A (es) |
ES (5) | ES2713482T3 (es) |
HR (3) | HRP20171078T1 (es) |
HU (3) | HUE044652T2 (es) |
IL (2) | IL220992A (es) |
LT (3) | LT3202460T (es) |
ME (2) | ME03441B (es) |
MX (3) | MX2012009237A (es) |
NI (1) | NI201200132A (es) |
NZ (3) | NZ717149A (es) |
PH (1) | PH12014501082B1 (es) |
PL (3) | PL2536706T3 (es) |
PT (3) | PT3202460T (es) |
RS (3) | RS58523B1 (es) |
RU (1) | RU2567753C2 (es) |
SG (3) | SG183257A1 (es) |
SI (3) | SI2536706T1 (es) |
TR (1) | TR201903027T4 (es) |
UA (2) | UA114856C2 (es) |
WO (1) | WO2011100380A1 (es) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010137547A1 (ja) | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
DK2536706T3 (en) * | 2010-02-11 | 2017-08-14 | Celgene Corp | ARYLMETHOXYISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPREHENSIVE AND PROCEDURES FOR USING SAME |
US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
US9365640B2 (en) | 2011-04-29 | 2016-06-14 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
CA3136093A1 (en) | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
US20140343058A1 (en) * | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
SG11201500983RA (en) * | 2012-08-09 | 2015-04-29 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
CN104837491A (zh) * | 2012-08-09 | 2015-08-12 | 细胞基因公司 | 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6-二酮治疗癌症的方法 |
AR094997A1 (es) * | 2012-08-09 | 2015-09-16 | Celgene Corp | Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos |
CN104718202B (zh) * | 2012-08-09 | 2018-11-20 | 细胞基因公司 | 用于制备(s)-3-(4-((4-(吗啉基甲基)苄基)氧基)-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮及其可药用形式的方法 |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
CN104797256A (zh) | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
AU2014205043B2 (en) | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
US9290475B2 (en) | 2013-03-14 | 2016-03-22 | Deuterx, Llc | 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
JP6493692B2 (ja) | 2013-03-15 | 2019-04-10 | セルジーン コーポレイション | 修飾されたtリンパ球 |
WO2014172429A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
UA117141C2 (uk) * | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
US20160313300A1 (en) * | 2013-12-06 | 2016-10-27 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
EP3131588A4 (en) * | 2014-04-14 | 2018-01-10 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
WO2015179276A1 (en) | 2014-05-19 | 2015-11-26 | Celgene Corporation | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
CA2957225A1 (en) | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
EP3182996B1 (en) | 2014-08-22 | 2022-12-28 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
ES2812877T3 (es) * | 2014-10-30 | 2021-03-18 | Kangpu Biopharmaceuticals Ltd | Derivado de isoindolina, producto intermedio, método de preparación, composición farmacéutica y uso del mismo |
KR20200052995A (ko) | 2015-01-20 | 2020-05-15 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법 |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
CN108026103B (zh) * | 2015-07-21 | 2021-04-16 | 伊缪诺金公司 | 制备细胞毒性苯并二氮杂䓬衍生物的方法 |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN |
JP6633744B2 (ja) * | 2015-09-29 | 2020-01-22 | カング バイオファーマシューティカルズ リミテッド | 医薬組成物及びその応用 |
US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
JP7001614B2 (ja) * | 2016-04-06 | 2022-02-03 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | リガンド依存性の標的タンパク質分解のための単官能性中間体 |
KR20180132861A (ko) * | 2016-04-12 | 2018-12-12 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bet 단백질 분해제 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
US10584101B2 (en) * | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
CN110167924A (zh) | 2016-10-28 | 2019-08-23 | 西奈山伊坎医学院 | 用于治疗ezh2介导的癌症的组合物和方法 |
CA3209295A1 (en) | 2016-11-01 | 2018-06-07 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
MX2019004621A (es) | 2016-11-02 | 2019-11-28 | Engmab Sarl | Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. |
RS64976B1 (sr) | 2016-12-01 | 2024-01-31 | Arvinas Operations Inc | Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora |
CN110267659A (zh) | 2016-12-08 | 2019-09-20 | 西奈山伊坎医学院 | 用于治疗cdk4/6介导的癌症的组合物和方法 |
CA3046869C (en) | 2016-12-16 | 2022-05-17 | Kangpu Biopharmaceuticals, Ltd. | Combination of a benzoheterocyclic compound and an androgen receptor pathway modulator for the treatment of prostate cancer |
EP3559002A4 (en) | 2016-12-23 | 2021-02-17 | Arvinas Operations, Inc. | CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE |
US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
KR102564201B1 (ko) | 2016-12-23 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
CN117551089A (zh) | 2017-01-26 | 2024-02-13 | 阿尔维纳斯运营股份有限公司 | ***受体蛋白水解调节剂及相关使用方法 |
US10434095B2 (en) | 2017-01-27 | 2019-10-08 | Celgene Corporation | 3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof |
JP2020510632A (ja) | 2017-02-03 | 2020-04-09 | セルジーン コーポレイション | セレブロンに対する小分子の親和性の測定方法 |
US20200000776A1 (en) * | 2017-02-13 | 2020-01-02 | Kangpu Biopharmaceuticals, Ltd. | Combination treating prostate cancer, pharmaceutical composition and treatment method |
CN108929307A (zh) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 |
CA3069138A1 (en) * | 2017-07-10 | 2019-01-17 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
CN111032628A (zh) | 2017-08-21 | 2020-04-17 | 细胞基因公司 | 制备(s)-4,5-二氨基-5-氧代戊酸叔丁酯的工艺 |
US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
AU2018336171B2 (en) | 2017-09-22 | 2023-01-05 | Jubilant Epipad LLC | Heterocyclic compounds as PAD inhibitors |
IL272667B (en) | 2017-10-18 | 2022-09-01 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
CN111655685B (zh) * | 2018-01-25 | 2023-11-17 | 藤本株式会社 | 噻吩衍生物及其用途 |
JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
EP3755718A1 (en) | 2018-02-21 | 2020-12-30 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
KR20200131845A (ko) | 2018-03-13 | 2020-11-24 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 상호작용/활성화 억제제로서의 비사이클릭 화합물 |
CA3095494C (en) | 2018-04-04 | 2023-11-07 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
SI3784663T1 (sl) | 2018-04-23 | 2023-11-30 | Celgene Corporation | Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
SG11202011872QA (en) * | 2018-07-10 | 2021-01-28 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
AU2019309894A1 (en) | 2018-07-27 | 2021-01-28 | Biotheryx, Inc. | Bifunctional compounds as CDK modulators |
US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
US20210317109A1 (en) * | 2018-09-07 | 2021-10-14 | Medshine Discovery Inc. | Tricyclic substituted piperidine dione compound |
KR20210069085A (ko) | 2018-09-30 | 2021-06-10 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 이소인돌린계 화합물, 이의 제조 방법, 약학 조성물 및 용도 |
WO2020072334A1 (en) | 2018-10-01 | 2020-04-09 | Celgene Corporation | Combination therapy for the treatment of cancer |
SG11202104411VA (en) | 2018-11-08 | 2021-05-28 | Juno Therapeutics Inc | Methods and combinations for treatment and t cell modulation |
EP3891128A4 (en) * | 2018-12-05 | 2022-08-17 | Vividion Therapeutics, Inc. | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT |
CA3122317C (en) * | 2018-12-06 | 2023-10-03 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound |
JP2022518175A (ja) * | 2019-01-09 | 2022-03-14 | セルジーン コーポレイション | (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む固体形態及びその塩、ならびにそれらを含む組成物及びその使用方法 |
BR112021013290A2 (pt) | 2019-01-09 | 2021-09-14 | Celgene Corporation | Compostos antiproliferativos e segundos agentes ativos para uso em tratar mieloma múltiplo |
EA202191904A1 (ru) * | 2019-01-09 | 2021-10-04 | Селджин Корпорейшн | Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения |
AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
MX2022005152A (es) | 2019-11-05 | 2022-06-29 | Celgene Corp | Uso de receptores de antigenos quimericos anti-bcma. |
JP2022554353A (ja) | 2019-11-07 | 2022-12-28 | ジュノー セラピューティクス インコーポレイテッド | T細胞療法と(s)-3-[4-(4-モルホリン-4-イルメチル-ベンジルオキシ)-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル]-ピペリジン-2,6-ジオンとの併用 |
WO2021105335A1 (en) | 2019-11-27 | 2021-06-03 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
EP4065571A1 (en) | 2019-11-27 | 2022-10-05 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
AU2020396866A1 (en) | 2019-12-02 | 2022-06-23 | Celgene Corporation | Therapy for the treatment of cancer |
MX2022007155A (es) | 2019-12-12 | 2022-10-07 | Accutar Biotechnology Inc | Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos. |
WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
AU2020410514A1 (en) * | 2019-12-18 | 2022-06-30 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
JP2023507570A (ja) | 2019-12-19 | 2023-02-24 | アルビナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体の標的分解のための化合物および方法 |
CN116234803A (zh) | 2019-12-23 | 2023-06-06 | 冰洲石生物科技公司 | 用于治疗癌症的***受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合 |
KR20220124228A (ko) | 2020-01-20 | 2022-09-13 | 강푸 바이오파마슈티칼즈 리미티드 | 이소인돌린 유도체, 및 이의 제약 조성물 및 용도 |
WO2021170021A1 (zh) * | 2020-02-25 | 2021-09-02 | 上海科技大学 | 基于戊二酰亚胺骨架的化合物及其应用 |
WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
EP4142722A1 (en) | 2020-04-30 | 2023-03-08 | Bristol-Myers Squibb Company | Methods of treating cytokine-related adverse events |
IL299293A (en) | 2020-06-25 | 2023-02-01 | Celgene Corp | Cancer treatment methods with combined treatments |
CN113896711A (zh) * | 2020-07-06 | 2022-01-07 | 北京诺诚健华医药科技有限公司 | 杂环类免疫调节剂 |
WO2022017365A1 (zh) * | 2020-07-20 | 2022-01-27 | 江苏恒瑞医药股份有限公司 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
KR20230048373A (ko) | 2020-08-03 | 2023-04-11 | 캡터 테라퓨틱스 에스.에이. | 저분자량 단백질 분해제 및 이의 응용 |
US20230310478A1 (en) * | 2020-09-02 | 2023-10-05 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
CA3191282A1 (en) | 2020-09-11 | 2022-03-17 | William Pierceall | Combination therapy for cancer |
WO2022066580A1 (en) * | 2020-09-23 | 2022-03-31 | Kinnate Biopharma Inc. | Raf degrading compounds |
CN116234553A (zh) * | 2020-10-02 | 2023-06-06 | 新基公司 | 治疗***性红斑狼疮的方法和作为对疗法临床敏感性的预测指标的生物标志物的用途 |
KR20230113755A (ko) | 2020-11-04 | 2023-08-01 | 셀진 코포레이션 | 선행 항암 알킬화제 요법을 받은 환자에서의 car t 세포 요법 |
CN112174976A (zh) * | 2020-11-19 | 2021-01-05 | 江西中医药大学 | 从水芹菜中分离的二苯并呋喃型木脂素及其方法和在抗痛风性关节炎上的用途 |
WO2022146151A1 (en) | 2020-12-30 | 2022-07-07 | Captor Therapeutics S.A. | Novel compounds which bind to cereblon, and methods of use thereof |
WO2022148358A1 (zh) * | 2021-01-05 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用 |
EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
IL305956A (en) * | 2021-03-31 | 2023-11-01 | Duke Street Bio Ltd | Pharmaceutical material |
WO2022255889A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
WO2022255890A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
WO2023025136A1 (zh) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | 异吲哚啉酮化合物及其用途 |
WO2023138647A1 (zh) * | 2022-01-19 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 一种含硫异吲哚啉类衍生物的晶型 |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
CN115160211B (zh) * | 2022-06-23 | 2023-11-03 | 温州大学 | 一种异吲哚啉酮类化合物的绿色合成方法 |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4421865A (en) * | 1981-06-08 | 1983-12-20 | Standard Oil Company (Sohio) | Selective hydrogen-deuterium interchange using ion exchange resins |
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5149820A (en) * | 1987-03-11 | 1992-09-22 | Norsk Hydro A.S. | Deuterated compounds |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5646154A (en) * | 1992-10-07 | 1997-07-08 | Sumitomo Pharmaceuticals Co., Ltd. | Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
UA60308C2 (uk) | 1996-07-24 | 2003-10-15 | Селджін Корпорейшн | ЗАМІЩЕНІ 2-(2,6-ДІОКСОПІПЕРИДИН-3-ІЛ)ФТАЛІМІДИ ТА 1-ОКСОІЗОІНДОЛІНИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЗНИЖЕННЯ РІВНЯ ФПН-α |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
CA2219698C (en) | 1996-10-31 | 2007-09-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
CA2275422A1 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
TR200101502T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
EP1182681B1 (en) | 2000-08-23 | 2006-03-01 | General Electric Company | Injection molded ceramic metal halide arc tube having non-tapered end |
US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
WO2003041326A2 (en) | 2001-11-09 | 2003-05-15 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
KR100793564B1 (ko) | 2002-05-17 | 2008-01-14 | 셀진 코포레이션 | 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물 |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CA2538864C (en) | 2003-09-17 | 2013-05-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
KR20110116225A (ko) | 2003-12-02 | 2011-10-25 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
EP2505200A1 (en) | 2004-03-22 | 2012-10-03 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
CN101163489A (zh) | 2004-04-23 | 2008-04-16 | 细胞基因公司 | 用于治疗和控制肺高血压的包含免疫调节化合物的组合物及其使用方法 |
US20090163548A1 (en) | 2004-05-05 | 2009-06-25 | Zeldis Jerome B | Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
RU2007105685A (ru) * | 2004-07-16 | 2008-08-27 | Шеринг Корпорейшн (US) | Производные гидантонина для лечения воспалительных заболеваний |
US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
NZ554068A (en) * | 2004-09-03 | 2009-07-31 | Celgene Corp | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines |
KR20070086000A (ko) | 2004-11-12 | 2007-08-27 | 셀진 코포레이션 | 기생충성 질병의 치료 및 관리를 위한 면역조절성 화합물을사용하는 방법 및 조성물 |
EP1827431A1 (en) | 2004-11-23 | 2007-09-05 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
NZ555886A (en) | 2004-12-01 | 2009-12-24 | Celgene Corp | Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders |
ME01513B (me) | 2005-06-30 | 2014-04-20 | Celgene Corp | Postupak dobijanja spojeva 4-amin0-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona |
MX2008002765A (es) | 2005-08-31 | 2008-04-07 | Celgene Corp | Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos. |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
ZA200901852B (en) | 2006-09-15 | 2010-06-30 | Celgene Corp | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
WO2008057196A2 (en) | 2006-10-19 | 2008-05-15 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases |
RU2471794C2 (ru) * | 2007-03-20 | 2013-01-10 | Селджин Корпорейшн | 4'-о-замещенные изоиндолиновые производные и содержащие их композиции и способы их применения |
DK2536706T3 (en) * | 2010-02-11 | 2017-08-14 | Celgene Corp | ARYLMETHOXYISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPREHENSIVE AND PROCEDURES FOR USING SAME |
WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
EP2640189A4 (en) | 2010-11-18 | 2014-03-19 | Deuteria Pharmaceuticals Inc | 3-deutero-pomalidomide |
WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
CA3136093A1 (en) | 2012-06-29 | 2014-01-03 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
CN104837491A (zh) | 2012-08-09 | 2015-08-12 | 细胞基因公司 | 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6-二酮治疗癌症的方法 |
US20140343058A1 (en) | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
CN104718202B (zh) | 2012-08-09 | 2018-11-20 | 细胞基因公司 | 用于制备(s)-3-(4-((4-(吗啉基甲基)苄基)氧基)-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮及其可药用形式的方法 |
SG11201500983RA (en) | 2012-08-09 | 2015-04-29 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
AR094997A1 (es) | 2012-08-09 | 2015-09-16 | Celgene Corp | Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
CN104797256A (zh) | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
NZ628320A (en) | 2013-03-14 | 2017-04-28 | Celgene Corp | Treatment of psoriatic arthritis using apremilast |
WO2014172429A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
US20160313300A1 (en) | 2013-12-06 | 2016-10-27 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2015179276A1 (en) | 2014-05-19 | 2015-11-26 | Celgene Corporation | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
WO2016025686A1 (en) | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
EP3207151A4 (en) | 2014-10-13 | 2018-07-04 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
ES2812877T3 (es) | 2014-10-30 | 2021-03-18 | Kangpu Biopharmaceuticals Ltd | Derivado de isoindolina, producto intermedio, método de preparación, composición farmacéutica y uso del mismo |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
-
2011
- 2011-02-10 DK DK11704156.6T patent/DK2536706T3/en active
- 2011-02-10 RU RU2012138709/04A patent/RU2567753C2/ru active
- 2011-02-10 EP EP23192393.9A patent/EP4289838A3/en active Pending
- 2011-02-10 MX MX2012009237A patent/MX2012009237A/es active IP Right Grant
- 2011-02-10 EP EP19178064.2A patent/EP3599236B1/en active Active
- 2011-02-10 SG SG2012059259A patent/SG183257A1/en unknown
- 2011-02-10 CN CN201180018485.1A patent/CN102822165B/zh active Active
- 2011-02-10 DK DK17157170.6T patent/DK3202460T3/da active
- 2011-02-10 NZ NZ717149A patent/NZ717149A/en unknown
- 2011-02-10 PT PT17157170T patent/PT3202460T/pt unknown
- 2011-02-10 EP EP16166423.0A patent/EP3106460B1/en active Active
- 2011-02-10 ES ES17157178T patent/ES2713482T3/es active Active
- 2011-02-10 ME MEP-2019-195A patent/ME03441B/me unknown
- 2011-02-10 JP JP2012552978A patent/JP2013519675A/ja not_active Withdrawn
- 2011-02-10 EP EP11704156.6A patent/EP2536706B1/en active Active
- 2011-02-10 US US13/025,105 patent/US8518972B2/en active Active
- 2011-02-10 LT LTEP17157170.6T patent/LT3202460T/lt unknown
- 2011-02-10 SG SG10202012179RA patent/SG10202012179RA/en unknown
- 2011-02-10 UA UAA201601384A patent/UA114856C2/uk unknown
- 2011-02-10 SI SI201131241T patent/SI2536706T1/sl unknown
- 2011-02-10 WO PCT/US2011/024269 patent/WO2011100380A1/en active Application Filing
- 2011-02-10 KR KR1020177036343A patent/KR101931468B1/ko active IP Right Grant
- 2011-02-10 RS RS20190249A patent/RS58523B1/sr unknown
- 2011-02-10 HU HUE17157170 patent/HUE044652T2/hu unknown
- 2011-02-10 SI SI201131680T patent/SI3202461T1/sl unknown
- 2011-02-10 EP EP17157178.9A patent/EP3202461B1/en active Active
- 2011-02-10 MX MX2016001880A patent/MX367522B/es unknown
- 2011-02-10 LT LTEP11704156.6T patent/LT2536706T/lt unknown
- 2011-02-10 DK DK17157178.9T patent/DK3202461T3/en active
- 2011-02-10 SI SI201131754T patent/SI3202460T1/sl unknown
- 2011-02-10 ES ES17157170T patent/ES2738776T3/es active Active
- 2011-02-10 ME MEP-2017-136A patent/ME02766B/me unknown
- 2011-02-10 PL PL11704156T patent/PL2536706T3/pl unknown
- 2011-02-10 ES ES11704156.6T patent/ES2638517T3/es active Active
- 2011-02-10 MX MX2013011071A patent/MX337169B/es unknown
- 2011-02-10 CN CN201510039358.XA patent/CN104693193B/zh active Active
- 2011-02-10 PT PT17157178T patent/PT3202461T/pt unknown
- 2011-02-10 UA UAA201210643A patent/UA115220C2/uk unknown
- 2011-02-10 HU HUE17157178A patent/HUE042011T2/hu unknown
- 2011-02-10 CA CA2787823A patent/CA2787823C/en active Active
- 2011-02-10 KR KR1020127023615A patent/KR101812356B1/ko active IP Right Grant
- 2011-02-10 PL PL17157170T patent/PL3202460T3/pl unknown
- 2011-02-10 TR TR2019/03027T patent/TR201903027T4/tr unknown
- 2011-02-10 EP EP17157170.6A patent/EP3202460B1/en active Active
- 2011-02-10 SG SG10201501062SA patent/SG10201501062SA/en unknown
- 2011-02-10 ES ES19178064T patent/ES2956743T3/es active Active
- 2011-02-10 LT LTEP17157178.9T patent/LT3202461T/lt unknown
- 2011-02-10 AU AU2011215877A patent/AU2011215877C1/en active Active
- 2011-02-10 NZ NZ601289A patent/NZ601289A/en unknown
- 2011-02-10 RS RS20170700A patent/RS56232B1/sr unknown
- 2011-02-10 PL PL17157178T patent/PL3202461T3/pl unknown
- 2011-02-10 HU HUE11704156A patent/HUE033009T2/en unknown
- 2011-02-10 NZ NZ700054A patent/NZ700054A/en unknown
- 2011-02-10 ES ES16166423T patent/ES2730763T3/es active Active
- 2011-02-10 RS RSP20190965 patent/RS59275B1/sr unknown
- 2011-02-10 PT PT117041566T patent/PT2536706T/pt unknown
- 2011-02-11 AR ARP110100436A patent/AR081058A1/es active IP Right Grant
-
2012
- 2012-07-17 IL IL220992A patent/IL220992A/en active IP Right Grant
- 2012-08-09 NI NI201200132A patent/NI201200132A/es unknown
- 2012-08-09 EC ECSP12012098 patent/ECSP12012098A/es unknown
- 2012-08-09 CR CR20120414A patent/CR20120414A/es unknown
- 2012-08-10 CO CO12135141A patent/CO6571916A2/es active IP Right Grant
-
2013
- 2013-07-26 US US13/952,386 patent/US9309219B2/en active Active
-
2014
- 2014-05-14 PH PH12014501082A patent/PH12014501082B1/en unknown
-
2016
- 2016-01-14 JP JP2016004951A patent/JP6215976B2/ja active Active
- 2016-02-10 US US15/040,980 patent/US9822094B2/en active Active
- 2016-02-10 US US15/040,971 patent/US9828361B2/en active Active
- 2016-04-13 JP JP2016080097A patent/JP2016172746A/ja not_active Withdrawn
- 2016-09-02 JP JP2016171451A patent/JP6270944B2/ja active Active
- 2016-11-08 IL IL248843A patent/IL248843B/en active IP Right Grant
-
2017
- 2017-06-27 JP JP2017125219A patent/JP2017200944A/ja active Pending
- 2017-07-13 HR HRP20171078TT patent/HRP20171078T1/hr unknown
- 2017-07-18 CY CY20171100759T patent/CY1119177T1/el unknown
- 2017-10-17 US US15/786,334 patent/US10189814B2/en active Active
-
2018
- 2018-11-19 US US16/195,550 patent/US10669257B2/en active Active
-
2019
- 2019-02-22 CY CY20191100227T patent/CY1121729T1/el unknown
- 2019-02-26 HR HRP20190368TT patent/HRP20190368T1/hr unknown
- 2019-07-19 HR HRP20191312TT patent/HRP20191312T1/hr unknown
- 2019-08-02 CY CY20191100823T patent/CY1121858T1/el unknown
-
2020
- 2020-03-31 US US16/836,832 patent/US11414399B2/en active Active
-
2022
- 2022-07-18 US US17/867,294 patent/US20220411402A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190368T1 (hr) | Derivati arilmetoksi izoindolina i pripravci koji ih sadrže te postupci njihove uporabe | |
EP2536756A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
EP2584897A4 (en) | COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE | |
EP2569425A4 (en) | ENDORIBONUCLEASE COMPOSITIONS AND METHOD FOR THEIR USE | |
EP2603201A4 (en) | LIPOSOME COMPOSITIONS AND USE METHOD THEREFOR | |
HK1175947A1 (en) | Pharmaceutical compositions and methods of making same | |
EP2596112A4 (en) | ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR | |
IL222969A0 (en) | Sweetener compositions and methods of preparing the same | |
EP2629742A4 (en) | HAIR CARE COMPOSITIONS AND RELATED METHODS | |
EP2588117A4 (en) | STABLE ANTISEPTIC COMPOSITIONS AND METHODS | |
IL220715A0 (en) | Nutritive compositions and methods of using same | |
HK1201451A1 (en) | Compositions and methods | |
EP2566485A4 (en) | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF | |
GB201018650D0 (en) | Methods and compositions | |
AU2010901846A0 (en) | Therapeutic methods and compositions | |
GB201018651D0 (en) | Methods and compositions | |
GB201010083D0 (en) | Compositions and methods | |
GB201009767D0 (en) | Compositions and methods | |
GB201003741D0 (en) | Methods and therapeutic compositions | |
AU2010901845A0 (en) | Cosmetic methods and compositions |